lencana Anda Rentang 52M $2–$5 1% of range Peringkat Analis BUY 8 analysts Target Harga $5 +146% upside P/E · ROE · Margin Laba Bersih ·

FBIO Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $2.03
Rentang 52M $2–$5

FBIO Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Pemecahan saham 1
Tanggal ex-dividen Pemecahan Tipe
10 Okt. 2023 1-for-15 Terbalik

Tentang Fortress Biotech, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

History

The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.

In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.

Subsidiaries

Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).

Products

Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.

== References ==

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan78 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Belum ada data untuk grup rasio ini

Data fundamental belum cukup untuk menghitung grup rasio ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata -50.7%
Laporan Berikutnya Nov 12, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Agu 13, 2026 $-0.08 $-0.20 60.8%
31 Maret 2026 Mei 13, 2026 $-1.13 $-0.22 -403.6%
31 Des. 2025 $-0.01 $0.11 -108.9%
30 Sep. 2025 $0.11 $-0.43 125.7%
30 Juni 2025 $-0.50 $-0.37 -36.2%
31 Maret 2025 $-0.48 $-0.50 4.9%
31 Des. 2024 $-0.75 $-0.77 2.4%

Pemilik institusional (13F) 65 pengaju · $21.2M total · Per tanggal 30 Juni 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 65
Nilai yang dipegang $21.2M
Posisi baru 14
Posisi yang keluar 11
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
14 (-2 vs Kuartal sebelumnya) 11 (+2 vs Kuartal sebelumnya) 15 (+3 vs Kuartal sebelumnya) 17 (-1 vs Kuartal sebelumnya) +547K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
VANGUARD GROUP INC $4.028.086 1.100.570 19,03% Saham
VANGUARD CAPITAL MANAGEMENT LLC $3.173.841 1.037.203 14,99% Saham
Opaleye Management Inc. $2.723.400 890.000 12,86% Saham
MACKENZIE FINANCIAL CORP $1.700.369 555.676 8,03% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1.089.360 356.000 5,15% Opsi jual
GEODE CAPITAL MANAGEMENT, LLC $919.944 300.521 4,35% Saham
BlackRock, Inc. $687.833 224.782 3,25% Saham
TWO SIGMA INVESTMENTS, LP $654.185 213.786 3,09% Saham
BRIDGEWAY CAPITAL MANAGEMENT, LLC $542.746 177.368 2,56% Saham
VANGUARD FIDUCIARY TRUST CO $509.095 166.371 2,40% Saham
HB Wealth Management, LLC $357.026 116.675 1,69% Saham
Kestra Advisory Services, LLC $355.679 116.235 1,68% Saham
STATE STREET CORP $310.899 101.601 1,47% Saham
GOLDMAN SACHS GROUP INC $294.855 96.358 1,39% Saham
Sheets Smith Investment Management $270.259 73.142 1,28% Saham
RENAISSANCE TECHNOLOGIES LLC $264.353 86.390 1,25% Saham
CITADEL ADVISORS LLC $235.819 77.065 1,11% Saham
Integrated Quantitative Investments LLC $210.198 68.692 0,99% Saham
PANAGORA ASSET MANAGEMENT INC $202.037 66.025 0,95% Saham
NORTHERN TRUST CORP $194.714 63.632 0,92% Saham
180 WEALTH ADVISORS, LLC $188.496 61.600 0,89% Saham
CITADEL ADVISORS LLC $178.704 58.400 0,84% Opsi jual
UBS Group AG $160.179 52.346 0,76% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $143.826 47.002 0,68% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $140.148 45.800 0,66% Opsi beli
Integrated Wealth Concepts LLC $138.312 45.200 0,65% Saham
WOLVERINE TRADING, LLC $129.480 33.200 0,61% Opsi jual
PRELUDE CAPITAL MANAGEMENT, LLC $127.011 41.507 0,60% Saham
WOLVERINE TRADING, LLC $124.800 32.000 0,59% Opsi beli
PFG Investments, LLC $111.693 36.501 0,53% Saham
CHOREO, LLC $110.925 36.250 0,52% Saham
JANE STREET GROUP, LLC $93.024 30.400 0,44% Opsi jual
TWO SIGMA ADVISERS, LP $92.415 25.250 0,44% Saham
JANE STREET GROUP, LLC $77.767 25.414 0,37% Saham
Cubist Systematic Strategies, LLC $77.347 20.933 0,37% Saham
Empowered Funds, LLC $76.500 25.000 0,36% Saham
Squarepoint Ops LLC $47.066 15.381 0,22% Saham
Corient Private Wealth LP $45.787 14.963 0,22% Saham
NewEdge Advisors, LLC $45.677 14.927 0,22% Saham
Abacus Planning Group, Inc. $44.474 14.534 0,21% Saham
SIMPLEX TRADING, LLC $44.394 14.508 0,21% Saham
Man Group plc $40.940 13.379 0,19% Saham
Vanguard Global Advisers, LLC $38.489 12.578 0,18% Saham
Weaver Consulting Group $31.724 10.367 0,15% Saham
Forum Financial Management, LP $30.600 10.000 0,14% Saham
OSAIC HOLDINGS, INC. $27.725 9.061 0,13% Saham
WELLS FARGO & COMPANY/MN $15.300 5.000 0,07% Saham
Rockefeller Capital Management L.P. $14.725 4.812 0,07% Saham
Arax Advisory Partners $12.503 4.086 0,06% Saham
SBI Securities Co., Ltd. $11.169 3.650 0,05% Saham

Tampilkan semua 65 pemilik institusional →

Aktivis & pemilik 5%+ 5 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Lindsay A. Rosenwald, M.D. ×3 pengajuan 20 Maret 2026 0,00% Amandemen · SEC
Fortress Biotech, Inc. ×30 pengajuan 6 Jan. 2026 13,40% Amandemen · SEC
Lindsay A Rosenwald, M.D. ×2 pengajuan 3 Jan. 2024 · Pengajuan awal · SEC
Michael S. Weiss ×4 pengajuan 21 Nov. 2023 · Pengajuan awal · SEC
Mr. Daryl Katz, DAK Capital Inc. ×2 pengajuan 14 Feb. 2023 · Pengajuan awal Investasi pasif SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 21 orang dalam · 11 pejabat · 13 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Lindsay A. Rosenwald, M.D. PRESIDENT, CEO & CHAIRMAN 18 Maret 2026 A 4.586.841 0 0 $0
Harlan F Weisman Chairman and CEO 20 Juni 2013 P 30.000 0 0 $0
David Jin Chief Financial Officer 1 April 2026 A 1.251.571 0 0 $0
Robyn Hunter Chief Financial Officer 21 Sep. 2021 S 163.877 0 0 $0
Bobby W Sandage PHD President 5 April 2013 G 22.311 0 0 $0
Noah D Beerman Executive VP and COO 31 Mei 2013 P 15.000 0 0 $0
Michael S Weiss Executive Vice Chairman 18 Maret 2026 A 2.276.562 0 0 $0
George Avgerinos SVP, BIOLOGICS OPERATIONS 17 April 2019 A 655.170 0 0 $0
Dale Ritter SVP & Chief Accounting Officer 31 Mei 2013 P 11.503 0 0 $0
Glenn L Cooper MD Executive Chairman of the Board 30 Nov. 2012 P 43.811 0 0 $0
Karin M. Hehenberger Executive Vice President; Chief Medical Officer 22 Juni 2012 P 20.925 0 0 $0
Dov Klein Direktur 1 Jan. 2026 A 130.105 0 0 $0
Jimmie Harvey Direktur 1 Jan. 2026 A 146.704 0 0 $0
Jay J Lobell Direktur 1 Jan. 2026 A 192.397 0 0 $0
Kevin Lorenz Direktur 1 Jan. 2025 A 73.687 0 0 $0
Lucy Lu Direktur 1 Jan. 2025 A 61.273 0 0 $0
Eric K Rowinsky Direktur 1 Jan. 2024 A 68.797 0 0 $0
David Jonathan Barrett Direktur 20 Feb. 2014 A 50.000 0 0 $0
Michael W Rogers Direktur 7 Feb. 2013 A · 0 0 $0
Malcolm Hoenlein · 1 Jan. 2026 A 115.747 0 0 $0
Kevin Horgan · 22 April 2014 M 0 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 3 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
IWC · iShares Trust 0,02% 87.563 SH 11 Sep. 2026 Harian
VXF · VANGUARD INDEX FUNDS 0,00% 311.095 SH 19 Agu 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,00% 697.802 SH 19 Agu 2026 Harian

FBIO Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 8 analis BELI
Target median $5.00 +146,3%
2 25,0% Beli Kuat
5 62,5% Beli
1 12,5% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

1 analis · 2026-09-29

Target rata-rata $5.00 +146,3%

Rendah$5.00 Rata-rata$5.00 Tinggi$5.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
FBIO · · · · · ·
ALDX $312M -9.2 · · -68.0% ·
SPRO $131M 15.5 39.2% 12.8% 18.7% ·
RNTX · -0.6 · · · ·
GRML · · · · -104.9% ·
XBIT · -1.6 · · · ·
APLM · -2.5 · -128.7% -1305.4% ·
IBIO $97M -5.5 -75.0% -33044.0% -65.7% ·
GOSS $724M -4.1 -57.7% -351.5% 201.8% ·
NMAD · · · · · ·

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.